January 26, 2025 07:03 PM ESTUpdated 08:31 AM
Pharma
FDA+

Ei­sai and Bio­gen win ap­proval for once-month­ly Leqem­bi main­te­nance dos­ing

Nicole DeFeudis

Editor

Ei­sai and Bio­gen scored an ap­proval for once-month­ly IV main­te­nance dos­ing of their Alzheimer’s drug Leqem­bi, as part of what they’ve said is an on­go­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Akero re­deems its fail­ure in se­vere MASH with longer-term da­ta

UK biotech launch­es with T cell ther­a­py tech­nol­o­gy to treat sol­id tu­mors

Maze looks to lead IPO queue with $113M Nas­daq de­but

Up­com­ing PDU­FA dates may be en­snared by Trump's pause at HHS, an­a­lyst says

Agenus con­tin­ues part­ner­ship talks for an­ti-CT­LA-4 com­bo with new Phase 2 da­ta

sponsored

Why the pre­mier re­cruit­ment agency in the world is giv­ing up re­cruit­ing, and spon­sors should, too

A service from the Financial Times